Uncategorized

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Innate Pharma SA announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program Read More »

REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries

REGiMMUNE Limited, a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech, a subsidiary of San Fu Chemical Co., Ltd. have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease in major Asian countries.

REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries Read More »

AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering

AnPac Bio-Medical Science Co., Ltd. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.

AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering Read More »

Scroll to Top